Probiotic-derived postbiotics: a perspective on next-generation therapeutics

The gut microbiome plays a fundamental role in regulating host immunity, metabolism, and overall health. Disruptions to this microbial ecosystem, known as dysbiosis, have been implicated in various conditions such as colorectal cancer, inflammatory bowel diseases, and metabolic syndromes. Although probiotics are widely used to restore microbial balance, their efficacy is often inconsistent due to variable colonization and concerns over antimicrobial resistance gene transfer. This review explores the growing body of literature surrounding postbiotics-bioactive metabolites produced by probiotics-as a promising alternative to live microbial therapy. We focus on key classes of postbiotics including exopolysaccharides, cell-free supernatants, short-chain fatty acids, and bacteriocins, summarizing their reported immunomodulatory, antimicrobial, antioxidant, and anti-cancer properties. We also highlight recent developments in formulation techniques, such as encapsulation, which enhance their stability and bioavailability. While current findings are promising, limitations persist, including variability in postbiotic composition and a lack of standardized clinical evaluations. Future research should aim to clarify their mechanisms of action, define optimal delivery strategies, and assess long-term safety. Overall, postbiotics present a sustainable, non-viable, and functionally rich alternative to probiotics, aligning with global health goals-Sustainable Development Goal 3 (Good Health and Well-being) and Sustainable Development Goal 9 (Industry, Innovation, and Infrastructure)-by offering safer, scalable, and effective therapeutic solutions.